Investigational Drug Gildeuretinol Demonstrates Efficacy in Stargardt Disease Trial

A clinical study published in JAMA Ophthalmology found that Alkeus Pharmaceuticals' gildeuretinol significantly reduced the growth rate of retinal atrophic lesions in Stargardt disease patients. The oral treatment was well-tolerated, with no reported dark adaptation delays or night blindness. This offers a promising potential long-term therapy for a condition currently lacking approved treatments to slow visual function loss, addressing a significant unmet medical need.